Jin-Yuan Chen

No ORCID on file · 1 paper in corpus · active 2026

Study types

  • article 1
article 2026
·doi:10.3389/fphar.2026.1860816

Background Elagolix and Myfembree are gonadotropin-releasing hormone (GnRH)-pathway therapies used for endometriosis, but their post-marketing safety reporting patterns remain incompletely characterized. Because spontaneous reporting databa…